By apyxmedical In 2020 Shareholder News, Case Study, J-Plasma, RenuvionPosted November 23, 2020APYX MEDICAL CORPORATION ANNOUNCES APPROVAL FROM FDA TO BEGIN PHASE II OF U.S. IDE STUDY READ MORE
By apyxmedical In 2020 Shareholder News, J-Plasma, RenuvionPosted November 9, 2020APYX MEDICAL CORPORATION REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS READ MORE
By apyxmedical In 2020 Shareholder News, Case Study, J-Plasma, RenuvionPosted November 9, 2020APYX MEDICAL CORPORATION ANNOUNCES UPDATES ON U.S. IDE CLINICAL STUDIES READ MORE
By apyxmedical In 2020 Shareholder News, J-Plasma, RenuvionPosted October 20, 2020APYX MEDICAL CORPORATION ANNOUNCES TWO PEER-REVIEWED CLINICAL PUBLICATIONS EVALUATING RENUVION’S HELIUM PLASMA TECHNOLOGY READ MORE
By apyxmedical In 2020 Shareholder News, J-Plasma, RenuvionPosted October 1, 2020APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2020 FINANCIAL RESULTS ON NOVEMBER 9, 2020 READ MORE
0 By apyxmedical In Posted September 17, 2020J-Plasma Clinical Reference – Kyriazanos, Extraperitoneal Access for Parietal Peritonectomy READ MORE
0 By apyxmedical In Posted September 17, 2020J-Plasma Clinical Reference – Barelkzi, Low Temperature Plasma on Prostate Cancer Cells READ MORE
By apyxmedical In 2020 Shareholder News, J-Plasma, RenuvionPosted August 31, 2020APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN SEPTEMBER READ MORE
By apyxmedical In 2020 Shareholder News, J-Plasma, RenuvionPosted August 7, 2020APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS READ MORE
